“…(−)-Epigallocatechin 3-gallate (EGCG), the major bioactive component of green tea catechins, has gained interest in OA research because of its potent anti-inflammatory and antioxidative properties [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. The chondroprotective effect of EGCG has been widely investigated using human articular chondrocytes [ 22 , 23 , 24 ], animal articular chondrocytes [ 25 , 26 ], bovine cartilage explants [ 27 ], and surgically induced OA animal models [ 28 , 29 , 30 ]. These studies have demonstrated that EGCG could mitigate OA progression by inhibiting the expression of proinflammatory genes (i.e., cyclooxygenase 2 (COX-2), matrix metalloproteinase-1(MMP-1), MMP-3, MMP-13, inducible nitric oxide synthase, tumor necrosis factor-α (TNF-α), transforming growth factor-β2, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5, aggrecanase-1, -2) [ 22 , 23 , 26 , 28 , 31 , 32 , 33 ], reducing the production of nitric oxide [ 22 , 34 ] and prostaglandin E2 [ 32 , 35 ], as well as increasing chondrogenic regeneration genes (i.e., aggrecan, collagen type II (Col II), and SOX9) [ 25 , 28 ].…”